1e
19
1
49
2
2
18
1b
1d
18
3c
8c
1d
2 29
1d
25
Kim A Reiss (Reiss Binder), MD
78
8c
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
28
90
3
5f
Assistant Program Director , Hematology/Oncology Fellowship at University of Pennsylvania
55
Member, Abramson Cancer Center
79
Co-Leader, Cancer Therapeutics Program, University of Pennsylvania
8b
Physician Lead, Pancreatic Cancer Clinical Research Unit, University of Pennsylvania
11
Department: Medicine
4
1
b
1d
46
Contact information
4d
4
3
3
3
2
4
b
1f
4d
Division of Hematology Oncology
2d Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
16 Office #10-305
39 3400 Civic Center Blvd
Philadelphia, PA 19104
26
2d Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
16 Office #10-305
39 3400 Civic Center Blvd
Philadelphia, PA 19104
2e
Office: 215-360-0735
32 Fax: 215-662-4646
24
f
32 Fax: 215-662-4646
24
13
Education:
21 7 BA 17 (Psychology) c
26 Colby College, 2002.
21 d Post BA 14 (Pre-Med) c
32 Johns Hopkins University , 2003.
21 7 MD 15 (Medicine) c
38 Penn State College of Medicine , 2008.
c
3
3
3
3
8d
Permanent link21 7 BA 17 (Psychology) c
26 Colby College, 2002.
21 d Post BA 14 (Pre-Med) c
32 Johns Hopkins University , 2003.
21 7 MD 15 (Medicine) c
38 Penn State College of Medicine , 2008.
c
2 29
21
1e
1d
24
2b
29
27
23
257 Sriram Anbil, Nicholas J. Seewald, E. Gabriela Chiorean, Maen Hussein, Pashtoon Murtaza Kasi, Doug E. Laux, Gary K. Schwartz, Geoffrey Shapiro, Kevin K. Lin, Marcia Craib, Lara Maloney, Karen McLachlan, Hanna Tukachinsky, Alexa B Schrock, Shuoguo Wang, Ethan S. Sokol, Brennan Decker, Katherine L. Nathanson Susan M. Domchek, Kim A. Reiss: LODESTAR: A Single Arm Phase II Study of Rucaparib in Solid Tumors with Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes. JCO Precision Oncology Jul 2025.
205 Susan M. Domchek, Alex Torres, Megan Aaron-Ocko, JoAnn Miller, Phil Seger, Hayley Knollman, Kim Reiss, Payal D. Shah, Matthew Morrow, Jeffrey Skolnik, Robert H. Vonderheide: Phase Ib study of a plasmid DNA–based immunotherapy encoding the hTERT, PSMA, and WT1 (INO-5401) +/- IL12 (INO-9012) followed by electroporation in cancer patients and healthy individuals with BRCA1/2 mutations. Oral Abstract Session, ASCO 2025, Chicago, IL June 2025.
25a Sriram Anbil, Nicholas J. Seewald, E. Gabriela Chiorean, Maen Hussein, Pashtoon Murtaza Kasi, Doug E. Laux, Gary K. Schwartz, Geoffrey Shapiro, Kevin K. Lin, Marcia Craib, Lara Maloney, Karen McLachlan, Hanna Tukachinsky, Alexa B Schrock, Shuoguo Wang, Ethan S. Sokol, Brennan Decker, Katherine L. Nathanson, Susan M. Domchek, Kim A. Reiss: LODESTAR: A single-arm phase II study of rucaparib in solid tumors with pathogenic germline or somatic variants in homologous recombination repair genes. ASCO 2025, Chicago, IL June 2025.
25c Uri Amit MD MPH PhD, James M Metz MD, John P Plastaras MD PhD, Rohi Gheewala MD, Peter O’Dwyer MD, Ursina Teitelbaum MD, Nevena Damjanov MD, Charles Vollmer MD, Charles J Schneider MD, Major Kenneth Lee IV, MD, PhD, Mark O’Hara MD, Kim A. Reiss MD, Erica L Carpenter PhD, Thomas B Karasic MD, Andre Konski MD, Rosmarie Mick, Paul Wileyto PhD and Edgar Ben-Josef MD: A Phase I Dual Dose Escalation Study of Radiation and Nab-paclitaxel in Patients with Unresectable and Borderline Resectable Pancreatic Cancer. Cancer June 2025.
1cb Bever KM, Durham JN, Qi H, Azad NS, Laheru D, Fisher GA, Greten TF, Hays J, Krishnamurthy A, Reiss KA, Sanborn R, Wang H, Diaz LA, Le DT: 10-year follow up of a phase 2 clinical trial of pembrolizumab (pembro) in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors (KEYNOTE-016). Rapid Oral Abstract Session, ASCO 2025, Chicago, IL June 2025.
1da Kim A. Reiss , Katherine Nathanson , Alexa B. Schrock, Alexander D. Fine, Derek W. Brown, Brennan Decker, Jason Hughes, Chang Xu, Bahar Yilmazel, Rebecca Hodges, Kimberly Johnson, Amaya Gasco, Hanna Tukachinsky: BRCA1/2 and PALB2 short variants (SVs) contributed by clonal hematopoiesis (CH) in liquid biopsies (LBx) from patients with advanced pancreatic cancer (PC). ASCO 2025, Chicago IL June 2025.
117 Kim A. Reiss MD, Kevin C Soares MD, MS, Robert J Trophy MD, PhD, Bishal Gyawali, MD, PhD, FASCO: Treatment innovations in pancreatic cancer: putting patient priorities first. ASCO Educational Book Apr 2025.
2b2 Kim A. Reiss, Mathew G. Angelos, E. Claire Dees, Yuan Yuan, Naoto T. Ueno, Paula R.Pohman, Melissa L. Johnson, Joseph Chao, Olga Shestova, Jonathan S. Serody, Maggie Schmierer, Madison Kremp, Michael Ball, Rehman Qureshi, Benjamin H. Schott, Poonam Sonawane, Sabrina Ceeraz DeLong, Melissa Christiano, Ramona F. Swaby, Sascha Abramson, Ken Locke, Debora Barton, Eugene Kennedy, Saar I. Gill, Daniel Cushing, Michael Klichinsky, Thomas Condamine, Yara Abdou: Chimeric antigen receptor macrophage therapy for HER2-overexpressing advanced solid tumors: A phase 1, first-in-human clinical trial. Nature Medicine Feb 2025.
2bd Alison M. Schram, Koichi Goto, Dong-Wan Kim, Teresa Macarulla, Antoine Hollebecque, Eileen M. O’Reilly, Sai-Hong Ignatius Ou, Jordi Rodon Ahnert, Sun Young Rha, Kazumi Nishino, Michaël Duruisseaux, Joon Oh Park, Cindy Neuzillet, Stephen V. Liu, Benjamin A. Weinberg, James M. Cleary, Emiliano Calvo, Kumiko Umemoto, Misako Nagasaka, Christoph Springfeld,Tanios Bekaii-Saab, Grainne M. O’Kane, Frans Opdam, Kim A. Reiss, Andrew K. Joe, Ernesto Wasserman, Viktoriya Stalbovskaya, Jim Ford, Shola Adeyemi, Lokesh Jain, Shekeab Jauhari, Alexander Drilon: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer. NEJM Feb 2025.
2c
7
1d
1f
Selected Publications
189 Emmanuel S. Antonarakis, Katherine L. Nathanson, Kim A. Reiss, Colin C. Pritchard, Jacob E. Berchuck, Kimberly Johnson, Derek W. Brown, Hanna Tukachinsky: CH mutations in 16,812 advanced cancer patients: Overestimation of CH-derived BRCA1/2 variants detected on liquid biopsy (Letter). Clinical Cancer Research Aug 2025.257 Sriram Anbil, Nicholas J. Seewald, E. Gabriela Chiorean, Maen Hussein, Pashtoon Murtaza Kasi, Doug E. Laux, Gary K. Schwartz, Geoffrey Shapiro, Kevin K. Lin, Marcia Craib, Lara Maloney, Karen McLachlan, Hanna Tukachinsky, Alexa B Schrock, Shuoguo Wang, Ethan S. Sokol, Brennan Decker, Katherine L. Nathanson Susan M. Domchek, Kim A. Reiss: LODESTAR: A Single Arm Phase II Study of Rucaparib in Solid Tumors with Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes. JCO Precision Oncology Jul 2025.
205 Susan M. Domchek, Alex Torres, Megan Aaron-Ocko, JoAnn Miller, Phil Seger, Hayley Knollman, Kim Reiss, Payal D. Shah, Matthew Morrow, Jeffrey Skolnik, Robert H. Vonderheide: Phase Ib study of a plasmid DNA–based immunotherapy encoding the hTERT, PSMA, and WT1 (INO-5401) +/- IL12 (INO-9012) followed by electroporation in cancer patients and healthy individuals with BRCA1/2 mutations. Oral Abstract Session, ASCO 2025, Chicago, IL June 2025.
25a Sriram Anbil, Nicholas J. Seewald, E. Gabriela Chiorean, Maen Hussein, Pashtoon Murtaza Kasi, Doug E. Laux, Gary K. Schwartz, Geoffrey Shapiro, Kevin K. Lin, Marcia Craib, Lara Maloney, Karen McLachlan, Hanna Tukachinsky, Alexa B Schrock, Shuoguo Wang, Ethan S. Sokol, Brennan Decker, Katherine L. Nathanson, Susan M. Domchek, Kim A. Reiss: LODESTAR: A single-arm phase II study of rucaparib in solid tumors with pathogenic germline or somatic variants in homologous recombination repair genes. ASCO 2025, Chicago, IL June 2025.
25c Uri Amit MD MPH PhD, James M Metz MD, John P Plastaras MD PhD, Rohi Gheewala MD, Peter O’Dwyer MD, Ursina Teitelbaum MD, Nevena Damjanov MD, Charles Vollmer MD, Charles J Schneider MD, Major Kenneth Lee IV, MD, PhD, Mark O’Hara MD, Kim A. Reiss MD, Erica L Carpenter PhD, Thomas B Karasic MD, Andre Konski MD, Rosmarie Mick, Paul Wileyto PhD and Edgar Ben-Josef MD: A Phase I Dual Dose Escalation Study of Radiation and Nab-paclitaxel in Patients with Unresectable and Borderline Resectable Pancreatic Cancer. Cancer June 2025.
1cb Bever KM, Durham JN, Qi H, Azad NS, Laheru D, Fisher GA, Greten TF, Hays J, Krishnamurthy A, Reiss KA, Sanborn R, Wang H, Diaz LA, Le DT: 10-year follow up of a phase 2 clinical trial of pembrolizumab (pembro) in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors (KEYNOTE-016). Rapid Oral Abstract Session, ASCO 2025, Chicago, IL June 2025.
1da Kim A. Reiss , Katherine Nathanson , Alexa B. Schrock, Alexander D. Fine, Derek W. Brown, Brennan Decker, Jason Hughes, Chang Xu, Bahar Yilmazel, Rebecca Hodges, Kimberly Johnson, Amaya Gasco, Hanna Tukachinsky: BRCA1/2 and PALB2 short variants (SVs) contributed by clonal hematopoiesis (CH) in liquid biopsies (LBx) from patients with advanced pancreatic cancer (PC). ASCO 2025, Chicago IL June 2025.
117 Kim A. Reiss MD, Kevin C Soares MD, MS, Robert J Trophy MD, PhD, Bishal Gyawali, MD, PhD, FASCO: Treatment innovations in pancreatic cancer: putting patient priorities first. ASCO Educational Book Apr 2025.
2b2 Kim A. Reiss, Mathew G. Angelos, E. Claire Dees, Yuan Yuan, Naoto T. Ueno, Paula R.Pohman, Melissa L. Johnson, Joseph Chao, Olga Shestova, Jonathan S. Serody, Maggie Schmierer, Madison Kremp, Michael Ball, Rehman Qureshi, Benjamin H. Schott, Poonam Sonawane, Sabrina Ceeraz DeLong, Melissa Christiano, Ramona F. Swaby, Sascha Abramson, Ken Locke, Debora Barton, Eugene Kennedy, Saar I. Gill, Daniel Cushing, Michael Klichinsky, Thomas Condamine, Yara Abdou: Chimeric antigen receptor macrophage therapy for HER2-overexpressing advanced solid tumors: A phase 1, first-in-human clinical trial. Nature Medicine Feb 2025.
2bd Alison M. Schram, Koichi Goto, Dong-Wan Kim, Teresa Macarulla, Antoine Hollebecque, Eileen M. O’Reilly, Sai-Hong Ignatius Ou, Jordi Rodon Ahnert, Sun Young Rha, Kazumi Nishino, Michaël Duruisseaux, Joon Oh Park, Cindy Neuzillet, Stephen V. Liu, Benjamin A. Weinberg, James M. Cleary, Emiliano Calvo, Kumiko Umemoto, Misako Nagasaka, Christoph Springfeld,Tanios Bekaii-Saab, Grainne M. O’Kane, Frans Opdam, Kim A. Reiss, Andrew K. Joe, Ernesto Wasserman, Viktoriya Stalbovskaya, Jim Ford, Shola Adeyemi, Lokesh Jain, Shekeab Jauhari, Alexander Drilon: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer. NEJM Feb 2025.
2c